HIV-Infektion - Entry-Inhibitoren im klinischen Einsatz: Was können wir erwarten?

Literatur

• 01 Lalezari J, Goodrich J, DeJesus E et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase IIb/III study in the US and Canada. 14^th CROI, Los Angeles 2007, abstract 104bLB. 
• 02 Nelson M, Fätkenheuer G, Konourina K et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results. 14^th CROI, Los Angeles 2007, abstract 104aLB. 

01 Maraviroc plus Optimized Therapy In Viremic Antiretroviral Treatment Experienced patients